Arbutus and Moderna agree to extend patent trial schedule to Sept 2025

Arbutus Biopharma Corp

Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.
Parties request trial start moved to September 24, 2025, subject to court approval.
Lawsuit seeks damages for patent infringement in manufacture and sale of MRNA-1273.
Stipulation cites need to accommodate outstanding discovery from Moderna and third parties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.